LY3314814

DRUG2 trials

Sponsors

AstraZeneca, Eli Lilly and Company

Conditions

HealthyHepatic Impairment

Phase 1

A Study of LY3314814 in Healthy Participants

CompletedNCT03222427

AstraZenecaHealthy

Start: 2018-01-15End: 2018-02-16Updated: 2019-10-31

A Study of LY3314814 in Participants With Liver Impairment

WithdrawnNCT03499041

Eli Lilly and CompanyHepatic Impairment

Start: 2018-06-30End: 2018-12-31Updated: 2018-06-28